Amgen Inc. (NASDAQ:AMGN) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, UBS analyst Trung Huynh raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $326 from $315 while keeping a Neutral rating on the shares.
A pharmacist filling a prescription for a complex drug developed by the company.
The firm told investors in a research note that it expects Amgen Inc. (NASDAQ:AMGN) to deliver a small beat in its Q2 results after two consecutive solid quarterly beats. However, it also continues to believe that the rare disease products may be bumpy.
Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.
While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
